CADScor®System launched in key markets
“Acarix introduced the CADScor®System on the German, Swedish and Danish markets 11 months ago, in June 2017. The introduction was made without general reimbursement, which is one of the key prerequisites and current priorities of the company for sustainable commercial success. During this period, we have sold 14 CADScor®Systems with the potential to significantly improve the diagnostic pathway for patients and non-invasive procedures, ruling out Coronary Artery Disease (CAD) with high accuracy. In general, the technology has been well received and there is broad acceptance for the need for disruption in the current diagnostic pathway.” Extract from interim CEO Christian Lindholm’s commentary to the Interim Report.
The complete interim report is available here. For further information, please contact: Christian Lindholm, interim CEO, +46 705 118 333, email@example.com This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on March 23, 2018. Notes to editors: Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team. The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patientspecific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.